Dimensional Fund Advisors LP Purchases 93,687 Shares of Qiagen (NYSE:QGEN)

Dimensional Fund Advisors LP grew its position in Qiagen (NYSE:QGENGet Rating) by 19.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 581,810 shares of the company’s stock after purchasing an additional 93,687 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.26% of Qiagen worth $24,018,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Massachusetts Financial Services Co. MA grew its position in shares of Qiagen by 0.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 20,487,835 shares of the company’s stock worth $845,738,000 after buying an additional 56,260 shares during the period. Vanguard Group Inc. increased its stake in Qiagen by 2.3% in the first quarter. Vanguard Group Inc. now owns 8,049,796 shares of the company’s stock valued at $394,440,000 after purchasing an additional 179,913 shares in the last quarter. Pendal Group Ltd raised its holdings in shares of Qiagen by 63.9% during the third quarter. Pendal Group Ltd now owns 5,258,339 shares of the company’s stock valued at $217,065,000 after purchasing an additional 2,049,960 shares during the period. Amundi boosted its position in shares of Qiagen by 10.5% during the 2nd quarter. Amundi now owns 3,865,333 shares of the company’s stock worth $177,846,000 after purchasing an additional 367,066 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Qiagen by 14.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,498,030 shares of the company’s stock worth $171,979,000 after purchasing an additional 434,472 shares in the last quarter. 58.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on QGEN shares. UBS Group upped their price target on Qiagen from $50.00 to $52.00 and gave the stock a “neutral” rating in a research note on Thursday, February 9th. Berenberg Bank lifted their price target on shares of Qiagen from €53.91 ($57.35) to €54.60 ($58.09) in a research report on Friday, November 11th. William Blair restated a “market perform” rating on shares of Qiagen in a report on Tuesday, November 8th. Finally, Citigroup lifted their price objective on shares of Qiagen from $55.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, February 9th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $55.53.

Qiagen Trading Up 1.2 %

NYSE QGEN opened at $46.33 on Monday. The company has a current ratio of 2.46, a quick ratio of 2.09 and a debt-to-equity ratio of 0.42. The business has a fifty day simple moving average of $49.00 and a 200 day simple moving average of $46.62. Qiagen has a 12 month low of $40.38 and a 12 month high of $51.18. The firm has a market capitalization of $10.52 billion, a P/E ratio of 25.18, a PEG ratio of 1.26 and a beta of 0.40.

Qiagen (NYSE:QGENGet Rating) last announced its earnings results on Tuesday, February 7th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.47 by $0.06. Qiagen had a net margin of 19.76% and a return on equity of 16.45%. The company had revenue of $531.00 million during the quarter, compared to the consensus estimate of $486.93 million. During the same quarter in the prior year, the company posted $0.74 earnings per share. The firm’s revenue for the quarter was down 8.8% on a year-over-year basis. On average, analysts predict that Qiagen will post 2.11 EPS for the current fiscal year.

Qiagen Company Profile

(Get Rating)

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis.

See Also

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGENGet Rating).

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.